Skip to main content

A phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma.

Publication ,  Journal Article
Antoine, EC; Rixe, O; Vuillemin, E; Benhammouda, A; Borel, C; Ghironzi, GC; Mularoni, E; Franks, C; Auclerc, G; Soubrane, C
Published in: Am J Clin Oncol
October 1995

Tamoxifen (TAM) has been reported to enhance cisplatin (CDDP) cytotoxicity in experimental and clinical melanoma studies. Based on our previous experience with sequential cisplatin-interleukin-2 (IL2)-interferon (IFN), we performed a phase II study of TAM combined with our original CDDP-IL2-IFN regimen in 22 pretreated metastatic melanoma patients. With a 41% response rate (95% CI, 21-61) we confirmed the interesting antitumor activity of CDDP-IL2-IFN combination; however, TAM enhanced neither the response rate nor the duration of response, but appeared to induce significantly more myelotoxicity, as compared to our previous results with CDDP-IL2-IFN alone. Whereas mechanisms by which TAM may modulate CDDP cytotoxicity in melanoma tumors remain unknown, the exact place of TAM, if any, and its safety in chemotherapeutic or chemoimmunotherapeutic combinations require further investigations.

Duke Scholars

Published In

Am J Clin Oncol

DOI

ISSN

0277-3732

Publication Date

October 1995

Volume

18

Issue

5

Start / End Page

421 / 424

Location

United States

Related Subject Headings

  • Tamoxifen
  • Recombinant Proteins
  • Oncology & Carcinogenesis
  • Middle Aged
  • Melanoma
  • Male
  • Interleukin-2
  • Interferon-alpha
  • Interferon alpha-2
  • Immunotherapy
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Antoine, E. C., Rixe, O., Vuillemin, E., Benhammouda, A., Borel, C., Ghironzi, G. C., … Soubrane, C. (1995). A phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma. Am J Clin Oncol, 18(5), 421–424. https://doi.org/10.1097/00000421-199510000-00012
Antoine, E. C., O. Rixe, E. Vuillemin, A. Benhammouda, C. Borel, G. C. Ghironzi, E. Mularoni, C. Franks, G. Auclerc, and C. Soubrane. “A phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma.Am J Clin Oncol 18, no. 5 (October 1995): 421–24. https://doi.org/10.1097/00000421-199510000-00012.
Antoine EC, Rixe O, Vuillemin E, Benhammouda A, Borel C, Ghironzi GC, et al. A phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma. Am J Clin Oncol. 1995 Oct;18(5):421–4.
Antoine, E. C., et al. “A phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma.Am J Clin Oncol, vol. 18, no. 5, Oct. 1995, pp. 421–24. Pubmed, doi:10.1097/00000421-199510000-00012.
Antoine EC, Rixe O, Vuillemin E, Benhammouda A, Borel C, Ghironzi GC, Mularoni E, Franks C, Auclerc G, Soubrane C. A phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma. Am J Clin Oncol. 1995 Oct;18(5):421–424.

Published In

Am J Clin Oncol

DOI

ISSN

0277-3732

Publication Date

October 1995

Volume

18

Issue

5

Start / End Page

421 / 424

Location

United States

Related Subject Headings

  • Tamoxifen
  • Recombinant Proteins
  • Oncology & Carcinogenesis
  • Middle Aged
  • Melanoma
  • Male
  • Interleukin-2
  • Interferon-alpha
  • Interferon alpha-2
  • Immunotherapy